Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05745896
Other study ID # 48740621.9.0000.5335
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date July 1, 2023
Est. completion date March 1, 2026

Study information

Verified date February 2023
Source Federal University of Health Science of Porto Alegre
Contact Talita Colombo, MD, MSc
Phone +55 51 3024 5657
Email talitacolombo@ufcspa.edu.br
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will compare the effectiveness of a prenatal care supported by telemedicine against usual care in low-risk pregnant women. The investigators will follow-up women in a gestational age of 6 weeks up to 41 weeks, and 6 postpartum weeks. The primary outcome is the anxiety level estimated by the General Anxiety Scale 7 scale (GAD-7 Scale).


Description:

This is a pragmatic, effectiveness, superiority randomized clinical trial (RCT), in which low risk pregnants will be randomized to a prenatal care program supported by telemedicine or usual care in an allocation ratio of 1:1. The follow-up period will last 41 weeks from inception (i.e., 6 to 13 weeks of gestational age) to pregnancy and a extension period of 6 weeks in the postpartum stage. The investigators settled anxiety levels estimated by the General Anxiety Scale 7 scale as primary outcome in a between-groups mean difference after the 3rd trimester. Secondary outcomes include: delivery mode, obstetric events and fetal and neonatal variables of epidemiological surveillance interest (birth weight, birth height and APGAR score; maternal, fetal and neonatal fatal and non-fatal events). The interventions will occur as follows: for usual care, all appointments (at least 9 outpatient clinic visits) will be carried forward in person by a senior obstetrician. Patients randomized for the telemedicine supported group should will attend at least 6 in person and 3 online appointments. All pregnant women will receive the standardized care throughout the study. The sample size calculation was based on the primary outcome, assuming between-groups mean difference of 4 points plus a 4-points standard deviation, at a statistical of 80% and a two-tailed 5% type I error. Further, a 15% of addition was done for potential impairments during the follow-up, ending in 30 patients per group. The m@mae-e study's setting will be the at Santa Casa de Misericórdia, (Porto Alegre, Brazil).


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 60
Est. completion date March 1, 2026
Est. primary completion date December 31, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 34 Years
Eligibility Inclusion Criteria: - Low-risk pregnant (as classified an attending physician and/or the study's obstetrician); - Gestational age less at 13 weeks or more in the moment of the first appointment; - Portuguese native speaker. Exclusion Criteria: - Pregnant involving: hypertension or diabetes mellitus (any type) previous diagnosis; - Obesity (BMI equal or greater than 35 m/kg2; - Previous diagnosis of severe Sars-CoV-2 2019-related (COVID-19) infection which needed hospitalization; - Previous thromboembolic event; - Acute or chronic hematological events/diseases; use of anticoagulants or anti platelet aggregation drugs; - Chronic cardiovascular, lung or kidney disease and cancer requiring treatment; - Immunosuppression state; - Severe mental disorder - major depression, generalized anxiety (and others anxiety-related disorders), bipolar disorder, schizophrenia and personality-related disorders in an uncontrolled manner for at least 1 year; - At least more than one abortion; - History of premature birth; - An enrolled patient living in the same house; - Plan to move the city.

Study Design


Intervention

Other:
Telemedicine appointment
Three online appointments for pregnancy monitoring at prenatal care.
Face-to-face appointment
Six to nine face-to-face appointments for pregnancy monitoring at prenatal care.

Locations

Country Name City State
Brazil Irmandade da Santa Casa de Misericórdia de Porto Alegre (ISCMPA) Porto Alegre Rio Grande Do Sul

Sponsors (5)

Lead Sponsor Collaborator
Talita Colombo Hospital de Clinicas de Porto Alegre, Irmandade Santa Casa de Misericórdia de Porto Alegre, McMaster University, VU University of Amsterdam

Country where clinical trial is conducted

Brazil, 

References & Publications (2)

Colombo T, Todeschini LB, Orlandini M, Nascimento HD, Gabriel FC, Alves RJV, Stein AT. Low-Risk Antenatal Care Enhanced by Telemedicine: A Practical Guideline Model. Rev Bras Ginecol Obstet. 2022 Sep;44(9):845-853. doi: 10.1055/s-0042-1753505. Epub 2022 Jul 19. — View Citation

Stein C, Helal L, Migliavaca CB, Sangalli CN, Colpani V, Raupp da Rosa P, Beck-da-Silva L, Rohde LE, Polanczyk CA, Falavigna M. Are the recommendation of sodium and fluid restriction in heart failure patients changing over the past years? A systematic review and meta-analysis. Clin Nutr ESPEN. 2022 Jun;49:129-137. doi: 10.1016/j.clnesp.2022.03.032. Epub 2022 Apr 6. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Anxiety levels in usual care and telemedicine support care groups from inception until the final of the prenatal care (6 weeks postpartum). Mean between-group differences in General Anxiety Disorder (GAD-7) scale scores. First measure at baseline, last measure at birth time
Primary Anxiety levels in usual care and telemedicine support care groups from inception until the final of the postpartum period (6 weeks postpartum). Mean between-group differences in General Anxiety Disorder (GAD-7) scale scores. First measure at baseline, last measure at the end of postpartum period (6 week postpartum).
Secondary Secondary analysis of anxiety levels between usual care and telemedicine support care groups. Mean between-groups differences in General Anxiety Disorder (GAD-7) scale scores. Repeated, full comparisons estimates at baseline; 10-12th weeks of pregnancy; 18-24 weeks of pregnancy and 34-36 weeks of pregnancy as well as the postpartum period (4-6 week postpartum)
Secondary Maternal fatal and non-fatal outcomes Cumulative incidence of gestational diabetes diagnosis; high blood pressure events (pre-eclampsia and eclampsia); severe anemia; need to forward to high-risk prenatal care program; cardiovascular events with or without hospitalization; cardiovascular attributable death during pregnancy and postpartum period; maternal attributable underlying cause of death; all-cause mortality. Assesed at birth
Secondary Fetal and neonatal fatal and non-fatal outcomes Cumulative incidence and mean difference between-groups of: gestational age at birth; birth weight; APGAR score; neonatal intensive care unit (ICU) admission; death by intentional and unintentional abortion; events related to underlying causes of fetal and neonatal periods; fatal events related to underlying causes of fetal and neonatal events Assesed at birth
Secondary Quality of life levels between usual care and telemedicine support care Mean between-groups differences in the Portuguese validated EuroQoL 5D scores (EQ-5D). Repeated, full comparisons estimates at baseline; 10-12th weeks of pregnancy; 18-24 weeks of pregnancy and 34-36 weeks of pregnancy as well as the postpartum period (4-6 week postpartum)
See also
  Status Clinical Trial Phase
Completed NCT05197634 - The Impact of Covid-19 Pandemic On The Children With Autism Spectrum Disorder
Recruiting NCT05918939 - UNAIR Inactivated COVID-19 Vaccine as Heterologue Booster (Immunobridging Study) Early Phase 1
Completed NCT05383560 - Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults Phase 2
Active, not recruiting NCT05125874 - Clinical Study for Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Immunization N/A
Completed NCT05517148 - Effects of an Immersive Virtual Reality Intervention Combined With Mindfulness-based Stress Reduction N/A
Completed NCT05552989 - Towards Better Preparedness for Future Catastrophes - Local Lessons-learned From COVID-19
Completed NCT05543551 - Effects of Diagrammatic Breathing With and Without Resistance in Post Covid Patients on ADLs N/A
Active, not recruiting NCT06272253 - UNAIR Inactivated COVID-19 Vaccine INAVAC as Heterologue Booster (Immunobridging Study) in Adolescent Subjects Early Phase 1
Active, not recruiting NCT05585567 - A Preliminary Exploratory Study to Evaluate the Safety and Immunogenicity of Omicron Variant Bivalent Vaccine V-01-B5 Early Phase 1
Not yet recruiting NCT05381883 - Mental Health of Professionals of the Silver Economy of New Aquitaine : Online Survey of Accommodation Establishments for Old People and Home Assistance Establishments N/A
Active, not recruiting NCT05582746 - COVID-19 Testing and Vaccine Literacy for Women With Criminal Legal System Involvement N/A
Recruiting NCT05062681 - RCT on the Efficacy of Dexamethasone Versus Methyl Prednisolone in Covid-19 Infected Patients With High Oxygen Flow Phase 4
Completed NCT04697030 - Burnout Among Adolescent Population During Covid-19 Lockdown in Pakistan
Active, not recruiting NCT05419167 - STEP-COVID: A Program for Pregnant Women During the SARS-CoV-2 Pandemic Phase 1
Completed NCT06435390 - Coronavirus Disease 2019 (COVID-19) Pandemic on the Oral Hygiene Status of Children
Terminated NCT05553964 - SARS-CoV-2 OTC At Home Test N/A
Completed NCT05596032 - Prospective Study to Validate the Diagnostic Performance of IVD CAPSULE COVID-19-NP Test for the Detection of SARS-CoV-2
Completed NCT05583812 - A Study of FB2001 for Inhalation in Healthy Chinese Adults Phase 1
Completed NCT05844410 - Evaluation of Corticosteroids Use and Clinical Outcomes in Hospitalized COVID-19 Patients: A Retrospective Study
Completed NCT05123573 - Self-Perceived in Medical Students Undergoing Distance Learning